No headlines found.
Aptose Reports Results for the Fourth Quarter and Full Year 2023
Globe Newswire (Tue, 26-Mar 4:01 PM ET)
Globe Newswire (Mon, 18-Mar 4:30 PM ET)
Globe Newswire (Wed, 31-Jan 4:01 PM ET)
Globe Newswire (Fri, 26-Jan 8:00 AM ET)
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
Aptose Biosciences - Common Shares trades on the NASDAQ stock market under the symbol APTO.
As of April 25, 2024, APTO stock price declined to $1.19 with 30,213 million shares trading.
APTO has a beta of -0.40, meaning it tends to be less sensitive to market movements. APTO has a correlation of 0.00 to the broad based SPY ETF.
APTO has a market cap of $18.69 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, APTO stock traded as high as $87.60 and as low as $1.17.
APTO has underperformed the market in the last year with a price return of -83.5% while the SPY ETF gained +23.1%. APTO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -43.1% and -13.8%, respectively, while the SPY returned +3.6% and -2.5%, respectively.
APTO support price is $1.15 and resistance is $1.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APTO stock will trade within this expected range on the day.